ConverGene has entered into an exclusive license agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. Under this agreement, ConverGene has the rights to commercialize jointly developed small molecule BET bromodomain inhibitors that have a unique core structure as compared to other cancer therapeutics currently in clinical trials.
{iframe}https://globenewswire.com/news-release/2016/12/13/897379/0/en/ConverGene-Announces-a-License-Agreement-With-the-National-Center-for-Advancing-Translational-Sciences.html{/iframe}